Targeted Cancer Therapy

An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer. Read More

A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models. Read More

Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment. Read More

Biomarker tests that help determine which patients may benefit from molecularly targeted therapies need better evidence and oversight to improve their effectiveness and availability, according to a study by the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine. Read More

Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients. Read More

Vanderbilt researchers have identified a new target for blocking breast cancer metastasis. Read More

Vanderbilt investigators have constructed a network map that could guide the development of new targeted cancer therapies. Read More

The protein MTBP is overexpressed in an aggressive type of breast cancer, and it regulates another protein implicated in many cancer types, suggesting that it may be a good target for new therapeutics. Read More

Inhibitors of a signaling pathway that is critical to synovial sarcoma tumorigenesis may be useful treatments for this aggressive cancer. Read More

Vanderbilt investigators have combined next-generation sequencing technologies and bioinformatics analyses to screen for genome-wide genetic mutations associated with drug resistance in a series of lung cancer cell lines. Read More

A protein associated with aggressive breast cancers may also influence resistance of lung cancer to targeted therapies. Read More